Chris Packard, Professor of Vascular Biochemistry at the University of Glasgow, UK, looks forward to fresh insights into the contrasting results of the REDUCE-IT and PROMINENT trials and the impact of changes in triglyceride-rich lipoproteins on atherosclerosis.
Derick Raal, Head of Lipidology and Endocrinology at Johannesburg Hospital, South Africa, anticipates research to further understand possible targets for ANGPTL3 and apoCIII inhibition, and outcome studies to establish their effects on cardiovascular events.
Rob Hegele, Jacob J Wolfe Distinguished Medical Research Chair, Robarts Research Institute, Ontario, Canada, hopes that patient genotyping in hypertriglyceridaemia trials will help predict response to novel therapies, and cardiovascular benefits.
Anne Goldberg, Professor of Medicine, Washington University School of Medicine, USA, is eager to find out if targeting apoCIII with antisense oligonucleotide or mRNA silencing approaches may lead the way to novel treatments for severe chylomicronaemia.
